In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2

BACKGROUND: Dolutegravir recently became the third integrase strand transfer inhibitor (INSTI) approved for use in HIV-1–infected individuals. In contrast to the extensive dataset for HIV-1, in vitro studies and clinical reports of dolutegravir for HIV-2 are limited. To evaluate the potential role o...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Robert A, Raugi, Dana N, Pan, Charlotte, Sow, Papa Salif, Seydi, Moussa, Mullins, James I, Gottlieb, Geoffrey S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4328052/
https://www.ncbi.nlm.nih.gov/pubmed/25808007
http://dx.doi.org/10.1186/s12977-015-0146-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4328052/
https://www.ncbi.nlm.nih.gov/pubmed/25808007
http://dx.doi.org/10.1186/s12977-015-0146-8

Ejemplares similares